ALEXANDRIA, Va., March 5 -- United States Patent no. 12,239,739, issued on March 4, was assigned to Novo Nordisk A/S (Bagsvaerd, Denmark).
"Oral dosing of GLP-1 compounds" was invented by Flemming S. Nielsen (Frederikssund, Denmark) and Per Sauerberg (Farum, Denmark).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to improved uses of glucagon-like peptide-1 (GLP-1) peptides in oral therapy."
The patent was filed on March 22, 2019, under Application No. 16/361,971.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=1...